Patent Issues in the Development of Biosimilar Medicines

Event details

21st July 2011
Notified soon

About the event


Biosimilar medicines are already a commercial reality in the European Union.  The U.S. Healthcare Reform legislation – with its defined pathway for the regulatory approval of follow-on biologics – should open up the U.S. market in the future, but in the meantime, the next batch of biosimilars will face other difficulties in reaching the market, both in the EU and elsewhere. SMi Group provides a CPD accredited masterclass which helps industry professionals to deal with patents issues during biosimilar medicine development for the EU market.


This event covers an extensive range of topics and provides a comprehensive survey and in-depth analysis of IP of biosimilars in advanced markets, specific, detailed focus on insulin analogues and pegylation, development of Monoclonal antibodies regulation and an outline of the future opportunities in developing markets and the EU. The masterclass is headed by an expert, Dr Duncan Curley (director of London-based law practice, Innovate Legal), who has in-depth knowledge and experience of IP law practice; where he has worked on many high-profile cases e.g. Lenzing v Courtaulds (fibre technology), Bespak v 3M (metered dose inhalers for asthma) and acts for a number of multinational companies on freedom to operate, patent clearance and litigation issues.


Gaining a deeper understanding into the IP of biosimilars is crucial to the dealing with the difficulties of them reaching the market, spotting future opportunities and developing strategies to help companies in the development of biosimilar medicines for the EU market.


Benefits of attending SMi’s CPD accredited masterclass, Patent Issues in the Development of Biosimilar Medicines:


Upon completion of this Masterclass, through a combination of presentations and interactive discussion, you will:


  • Analysethe IP of biosimilars in advanced markets
  • Discusspatent issues that may arise during the development of biosimilar medicines for the EU market
  • Debatecase studies involving IP evolution, cost effectiveness and business models
  • Gain knowledgeabout the development of Monoclonal antibodies regulation
  • Learn from an extremely experienced Masterclass leader with in-depth and specific knowledge of IP legal practice in the pharmaceutical sector
  • Gain valuable CPD points through attendance


For further information and the opportunity to register online please visit;

Exhibitor information


The aim of SMi is Linking Business with Information through the delivery of high quality business to business information services. Our overriding advantage is our flexibility and ability to respond quickly to the requirements and needs of all our customers, ensuring that all SMi products are highly relevant, innovative and timely.


The SMi Group is a world leader in business to business information. Within the past year thousands of senior executives from blue chip companies benefited from SMi's highly targeted conferences, workshops and masterclasses.


As a market research based organisation, SMi takes pride in the quality of its programmes and documentation, ensuring that they are brought to the attention of the key decision makers in each industry sector in which it operates. We cultivate and maintain strong industry contacts to ensure that we are informed of all pending changes in government and regulatory policy, and we regard our relationships with speakers, delegates and subscribers as an investment for the future.